JCLA:MiR-126与银屑病病情加重相关

2019-01-18 MedSci MedSci原创

MiR-126与银屑病病情加重相关,可促进角质形成细胞增殖和炎症及抑制细胞凋亡。 本研究旨在探讨miR-126在银屑病病灶皮肤中的表达及其与临床特征的相关性,探讨miR-126上调对人角质形成细胞增殖、凋亡和炎症的影响。 研究人员对102例银屑病患者进行随访。采用定量聚合酶链反应(qPCR)检测MiR 126在病变皮肤和非病变配对样本皮肤中的表达。采用miR-126模拟质粒和空白模拟质

MiR-126与银屑病病情加重相关,可促进角质形成细胞增殖和炎症及抑制细胞凋亡。

本研究旨在探讨miR-126在银屑病病灶皮肤中的表达及其与临床特征的相关性,探讨miR-126上调对人角质形成细胞增殖、凋亡和炎症的影响。

研究人员对102例银屑病患者进行随访。采用定量聚合酶链反应(qPCR)检测MiR 126在病变皮肤和非病变配对样本皮肤中的表达。采用miR-126模拟质粒和空白模拟质粒转染人角质形成细胞(HaCaT细胞)。采用细胞计数试剂盒8annexin V/丙碘化钠检测细胞的增殖和凋亡,并利用Western blot检测凋亡标志物(cleaved caspase 3 [C caspase 3]B细胞淋巴瘤2 [Bcl 2])蛋白水平。采用qPCRWestern blot检测炎性细胞因子mRNA和蛋白水平。

研究结果显示MiR-126在皮损组织中的表达水平高于非皮损成对组织,其表达水平与银屑病患者的皮损面积和严重程度指数评分呈正相关。MiR-126模拟物组经质粒转染HaCaT细胞后,MiR-126表达较阴性对照(NC)模拟组升高,MiR-126模拟组细胞增殖增强,细胞凋亡率低于NC模拟组。caspasebcl2的蛋白表达也表明miR 126 模拟物降低了细胞的凋亡。此外,mir- 126模拟增加肿瘤坏死因子α干扰素γ,IL 17 aIL 22表达式而降低IL 10的表达。综上所述,miR 126与银屑病患者患病风险升高、病情加重相关, miR 126的上调可促进角质形成细胞增殖和炎症,抑制细胞凋亡。

原始出处:

Shike Feng, Lin Wang, Wang Liu, MiR126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells' apoptosis in psoriasis

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765071, encodeId=f4d21e6507195, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 07 19:50:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930676, encodeId=491019306e6bf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri May 31 22:50:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935514, encodeId=b5c519355147e, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Thu May 30 10:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799550, encodeId=2b8d1e99550f5, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat May 25 06:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765071, encodeId=f4d21e6507195, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 07 19:50:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930676, encodeId=491019306e6bf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri May 31 22:50:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935514, encodeId=b5c519355147e, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Thu May 30 10:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799550, encodeId=2b8d1e99550f5, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat May 25 06:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-31 smallant2002
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765071, encodeId=f4d21e6507195, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 07 19:50:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930676, encodeId=491019306e6bf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri May 31 22:50:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935514, encodeId=b5c519355147e, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Thu May 30 10:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799550, encodeId=2b8d1e99550f5, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat May 25 06:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765071, encodeId=f4d21e6507195, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 07 19:50:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930676, encodeId=491019306e6bf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri May 31 22:50:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935514, encodeId=b5c519355147e, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Thu May 30 10:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799550, encodeId=2b8d1e99550f5, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat May 25 06:50:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]

相关资讯

Arthritis Rheumatol:中重度慢性斑块状银屑病患者乌司奴单抗治疗后,外周亚临床肌腱端病的消退

抑制银屑病的IL-12/23在治疗后12周内抑制了亚临床肌腱端病,并维持到52周。

EBioMedicine:王宏林教授揭示乳香活性成分治疗银屑病新靶点和机制

MAT2A蛋白、单碳循环有可能成为干预银屑病的新靶点和新机制。 研究图 摄 乳香是阿拉伯、印度、中国等国自古沿用至今的传统药物,具有抗炎、抗感染等多种功效。AKBA是乳香中最重要的活性成分。   上海交通大学医学院、上海市免疫学研究所王宏林领衔课题组的最新研究率先揭示了传统药物乳香中活性小分子化合物AKBA的作用靶点和作用机制,从而找到干预银屑病的新靶点和新机制。相关论文在线发表于Th

Clin Exp Rheumatol:血清钙卫蛋白可作为早期银屑病和类风湿性关节炎滑膜炎的标志物

早期PsA中,血清钙卫蛋白与疾病活动性的超声指标相关。

NEJM:指甲点蚀样改变-病例报道

银屑病患者指甲变化的症状包括变色(例如,黄色或粉红色变色区域称为油滴变色或鲑鱼斑),甲剥离,甲下角化过度,甲板破碎和分裂出血。可以看到指甲点蚀的其他病症包括斑秃、湿疹性皮炎和创伤性职业性损伤。孤立的凹坑可以在正常的指甲中发生。

Arthritis Rheumatol:银屑病关节炎相关新型自身抗体的识别

这项研究结果表明,这些自身抗体可能是有用的生物标志物,并提示了银屑病和银屑病关节炎的治疗靶点。

Semin Arthritis Rheu:银屑病关节炎的功能障碍测定

HAQ-DI是一种有价值的评估工具,临床医生应该继续在临床试验和实践中使用。